Article
Peripheral Vascular Disease
Carmine Savoia, Carolina De Ciuceis, Anna Paini, Raffaella Carletti, Emanuele Arrabito, Carmine Nicoletti, Paolo Mercantini, Cira Di Gioia, Allegra Battistoni, Sarassunta Ucci, Antonio Filippini, Enrico Agabiti Rosei, Massimo Volpe, Maria L. Muiesan, Damiano Rizzoni, Massimo Salvetti
Summary: In this study, chronic treatment with the direct renin inhibitor aliskiren significantly improved vascular function in both resistance and conduit arteries of type two diabetic and hypertensive patients. Aliskiren restored endothelial function and induced a more prompt peripheral vasodilation, possibly through increased production of nitric oxide via enhanced expression and function of the active phosphorylated form of endothelial nitric oxide synthase, compared to ramipril.
JOURNAL OF HYPERTENSION
(2021)
Review
Medicine, General & Internal
Jiantong Shen, Wenming Feng, Yike Wang, Qiyuan Zhao, Billong Laura Flavorta, Jingya Lu
Summary: This study aims to comprehensively evaluate the efficacy, safety, and tolerability of aliskiren combination therapy for hypertension patients through a synthesis of systematic reviews and meta-analyses. The evidence will be systematically reviewed using a mixed-methods approach, with the results being reported in summary of findings tables and iteratively mapped for analysis.
Article
Biochemistry & Molecular Biology
Abdel-Mohsen S. A. Ismail, Gamal El-Deen A. Helal, Doaa M. A. El-Khouly, Mona A. Esawy
Summary: This research aimed to invent a new method for cheese making using Rennin-like enzyme from fungus with high efficiency and reusability. Rhizomucor miehei (CBS: 370.65) showed promising milk clotting activity and negative mycotoxin test. The immobilized enzyme displayed better stability and could be reused more than sixteen times in cheese production. The immobilization process reduced the activation energy and calcium ions had a stimulating effect on enzyme activity. Buffalo milk and full cream milk showed the highest immobilized enzyme activity among the substrates tested.
INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
(2022)
Article
Immunology
Yi Lin, Kaitao Wang, Taotao Zhou, Zhefeng Meng, Qicheng Lan, Zhikai Jiang, Yuting Lin, Jianpeng Chen, Dingsheng Lin
Summary: A study found that aliskiren can improve flap survival and reduce the risk of necrosis after surgery. This may be because aliskiren can reduce ischemia-reperfusion injury, improve flap blood perfusion and angiogenesis, and decrease the levels of inflammatory factors.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2023)
Article
Medicine, Research & Experimental
Mohamed Essam, Nashwa Barakat, Ahmed Elkashef, Amira Awadalla, A. E. Behery, Mahmoud Abdel-Maboud
Summary: The study showed that aliskiren significantly improved renal function, reduced necrosis and inflammatory cell infiltration in the cortex and medulla during acute and chronic partial ureteral obstruction in rat solitary kidney. Aliskiren also upregulated BCL-2 and downregulated IL-6, TGF-beta 1, collagen I, and fibronectin gene expression, while increasing GSH and SOD activity and reducing MDA and NO activity, leading to a more renoprotective effect when administered for four weeks compared to two weeks.
Article
Biochemistry & Molecular Biology
Erard Vergoten, Christian Bailly
Summary: The renin protein and ACE2 play crucial roles in regulating blood pressure and facilitating SARS-CoV-2 virus entry into host cells. Studies have shown that renin inhibitors like remikiren and aliskiren can interact with the viral main protease M-pro, suggesting potential antiviral effects. The binding of these inhibitors to M-pro suggests a promising avenue for drug development against COVID-19.
JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
(2022)
Article
Neurosciences
Sami Alzarea, Hassan H. Alhassan, Abdulaziz Alzarea, Ziad H. Al-Oanzi, Muhammad Afzal
Summary: The study aims to determine the impact of renin inhibitor Aliskiren on lipopolysaccharide-induced depressive-like behavior and neuroinflammation in mice. The results demonstrate that Aliskiren can mitigate the negative effects of lipopolysaccharide on mouse behavior and brain inflammation.
Review
Pharmacology & Pharmacy
Hae Jin Kee, Inkyeom Kim, Myung Ho Jeong
Summary: This article provides an overview of the pathogenesis of hypertension, current anti-hypertensive drugs, and the need for novel drugs. It focuses on the role and regulatory mechanisms of HDACs in hypertension and discusses the progress in developing HDAC inhibitors as potential therapeutic targets.
BIOCHEMICAL PHARMACOLOGY
(2022)
Article
Pharmacology & Pharmacy
Jianing Chen, Yaokai Wen, Xiangling Chu, Yuzhi Liu, Chunxia Su
Summary: This study revealed the unique adverse event profile of NSCLC patients with hypertension receiving anti-PD-1/PD-L1 inhibitors, showing that patients with hypertension were more prone to reporting interstitial lung disease when undergoing anti-PD-1 treatment.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Biochemistry & Molecular Biology
I-Chen Chen, Yi-Ching Liu, Yen-Hsien Wu, Shih-Hsing Lo, Shu-Chi Wang, Chia-Yang Li, Zen-Kong Dai, Jong-Hau Hsu, Chung-Yu Yeh, Yu-Hsin Tseng
Summary: Pulmonary hypertension (PH) is a severe progressive disease caused by the uncontrolled proliferation of pulmonary artery smooth muscle cells (PASMCs). The down-regulation of Mitofusin-2 (MFN2) is known to contribute to PH. In this study, it was found that hypoxia increases the viability and reduces the expression of MFN2 in PASMCs. However, MFN2 overexpression and the use of proteasome inhibitors restored MFN2 expression, inhibited hypoxia-induced proliferation, and induced the expression of cleaved-PARP1, suggesting their potential in improving the hypoxia-induced proliferation of PASMCs.
Review
Pharmacology & Pharmacy
Olga Mulas, Giovanni Caocci, Brunella Mola, Giorgio La Nasa
Summary: This study found that hypertension is a common cardiovascular complication in CML patients treated with second- or third-generation TKI. Compared to the first-generation imatinib, nilotinib and ponatinib were both associated with a significantly increased risk of hypertension.
FRONTIERS IN PHARMACOLOGY
(2021)
Review
Biochemistry & Molecular Biology
Marianna Nalli, Domiziana Masci, Andrea Urbani, Giuseppe La Regina, Romano Silvestri
Summary: This review discusses the recent advances in small molecule beta-catenin agents, including the structure-activity relationships and biological activities of inhibitors, providing useful knowledge for the discovery of therapeutic beta-catenin drugs for cancer treatment.
Article
Biochemistry & Molecular Biology
Hui Zhang, Aya Laux, Kurt R. Stenmark, Cheng-Jun Hu
Summary: The study reveals reduced levels of mature miRNAs in pulmonary artery fibroblasts from IPAH patients, which can be restored by HDACi. It was found that decreased miR-124 levels in PH-Fibs are mainly due to reduced gene transcription, and HDACi can relax chromatin structure to increase miR-124-1 gene transcription. The data suggest epigenetic events play a crucial role in controlling miRNA levels in chronic pulmonary hypertension.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Chemistry, Multidisciplinary
Taslim A. Al-Hilal, Mohammad Anwar Hossain, Ahmed Alobaida, Farzana Alam, Ali Keshavarz, Eva Nozik-Grayck, Kurt R. Stenmark, Nadezhda A. German, Fakhrul Ahsan
Summary: The study developed a hypoxia-activated prodrug of fasudil that selectively suppresses ROCK activity under hypoxic conditions, exhibiting antiproliferative effects on disease-afflicted pulmonary arterial smooth muscle cells and pulmonary arterial endothelial cells. The prodrug has a long plasma half-life and does not affect systemic blood pressure.
JOURNAL OF CONTROLLED RELEASE
(2021)
Review
Cardiac & Cardiovascular Systems
Sebastian D. Sahli, Clara Castellucci, Tadzio R. Roche, Julian Roessler, Donat R. Spahn, Alexander Kaserer
Summary: This review summarizes the evidence of viscoelastic tests for assessing residual direct oral anticoagulant (DOAC) activity. The results show that DOAC-specific assays are more sensitive in evaluating DOAC activity, while unspecific assays have limited sensitivity. The clinical utility of existing viscoelastic test methods in excluding residual DOAC plasma levels is limited.
FRONTIERS IN CARDIOVASCULAR MEDICINE
(2022)
Article
Oncology
M. P. Jadhav, V. M. Shinde, S. Chandrakala, F. Jijina, H. Menon, B. Arora, P. A. Kurkure, P. M. Parikh, N. A. Kshirsagar
INDIAN JOURNAL OF CANCER
(2012)
Article
Pharmacology & Pharmacy
M. P. Jadhav, Mangal S. Nagarsenker, R. V. Gaikwad, A. Samad, Nilima A. Kshirsagar
INDIAN JOURNAL OF PHARMACEUTICAL SCIENCES
(2011)
Article
Medicine, General & Internal
M. P. Jadhav, A. Bamba, V. M. Shinde, N. Gogtay, N. A. Kshirsagar, L. S. Bichile, D. Mathai, A. Sharma, S. Varma, R. Digumarathi
JOURNAL OF POSTGRADUATE MEDICINE
(2010)
Article
Pharmacology & Pharmacy
Manoj Jadhav, Priyanka Jadhav, Vishal Shinde, Prashant Kadam, Nilima Kshirsagar
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT
(2013)